CABA Cabaletta Bio
- 2.380
- +0.070+3.03%
- 2.400
- +0.020+0.84%
Cabaletta Bio News
Wells Fargo Downgrades Cabaletta Bio(CABA.US) to Hold Rating, Cuts Target Price to $6
Evercore Initiates Cabaletta Bio(CABA.US) With Hold Rating, Announces Target Price $6
Analysts Conflicted on These Healthcare Names: Verastem (VSTM), Roche Holding AG (OtherRHHVF) and Cabaletta Bio (CABA)
BofA Securities Cuts Price Target on Cabaletta Bio to $29 From $31, Keeps Neutral Rating
Cabaletta Bio Cut to In-Line From Outperform by Evercore ISI Group
Evercore ISI Group Downgrades Cabaletta Bio to In-Line, Lowers Price Target to $6
Cabaletta Bio Analyst Ratings
Wells Fargo Downgrades Cabaletta Bio to Equalweight From Overweight, Cuts Price Target to $6 From $12
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $25
William Blair Maintains Cabaletta Bio(CABA.US) With Buy Rating
Cabaletta Bio Is Maintained at Overweight by Wells Fargo
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $25
A Quick Look at Today's Ratings for Cabaletta Bio(CABA.US), With a Forecast Between $12 to $25
Cabaletta Bio Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
Cabaletta Bio Analyst Ratings
Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Cabaletta Bio (CABA) and Mersana Therapeutics (MRSN)
Cabaletta Bio's Promising Trial Results and Proactive Management Secure Buy Rating
Stifel Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $26
Cabaletta Bio Analyst Ratings
UBS Initiates Cabaletta Bio(CABA.US) With Buy Rating, Announces Target Price $10
No Data